SCA
ALNY icon

SAC Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

SAC Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-140,522
Closed -$9.44M – 53
2014
Q1 		$9.44M Buy
140,522
+95,087
+209% +$7.36M 0.05% 419
2013
Q4 		$2.92M Sell
45,435
-19,565
-30% -$1.17M 0.02% 611
2013
Q3 		$4.16M Sell
65,000
-555,449
-90% -$27.7M 0.02% 565
2013
Q2 		$19.2M Buy
+620,449
New +$16.5M 0.11% 250

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SAC Capital Advisors's ALNY Position: Q2 2014 in Review

SAC Capital Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2014, closing a stake of 140,522 shares — an estimated $9.44M sold.

SAC Capital Advisors first reported a position in ALNY in Q2 2013 and held it in 4 quarters. The position peaked at $19.2M in Q2 2013. 193 funds tracked by Wall St. Rank hold ALNY as of Q2 2014.

  • SAC Capital Advisors reported no remaining Alnylam Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 140,522 Alnylam Pharmaceuticals shares in Q2 2014, an estimated $9.44M.
  • SAC Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • SAC Capital Advisors's Alnylam Pharmaceuticals position peaked at $19.2M in Q2 2013.
  • 193 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.